Sofía Mercedes Narvaez‐Chávez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sofía Mercedes Narvaez‐Chávez has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Aldo Torre
Gastroenterology Department ABC Medical Center Mexico City Mexico
1 shared publication - Carlos Alberto Aguilar Salinas
Dirección de Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Ciudad de México, México...
1 shared publication - Froylan David Martínez-Sánchez
Facultad de Medicina Universidad Nacional Autónoma de Mexico Mexico City Mexico
1 shared publication - Jacqueline Cordova-Gallardo
Hospital General Manuel Gea González Mexico City Mexico
1 shared publication - Mariana Ariel Herrera‐Islas
Facultad de Medicina Universidad Nacional Autónoma de Mexico Mexico City Mexico
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 5 July 2024
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 12 (7) , e1335
Pirfenidone use in fibrotic diseases: What do we know so far?
Background: Pirfenidone has demonstrated significant anti‐inflammatory and antifibrotic effects in both animal models and some clinical trials. Its potential for antifibrotic activity positions it as a promising candidate for the treatment of various fibrotic diseases. Pirfenidone exerts several pleiotropic and anti‐inflammatory effects through different molecular pathways, attenuating multiple inflammatory processes, including the secretion of pro‐inflammatory cytokines, apoptosis, and fibroblast activation.Objective: To present the current evidence of pirfenidone's effects on several fibrotic diseases, with a focus on its potential as a therapeutic option for managing chronic fibrotic conditions.Findings: Pirfenidone has been extensively studied for idiopathic pulmonary fibrosis, showing a favorable impact and forming part of the current treatment regimen for this disease. Additionally, pirfenidone appears to have beneficial effects on similar fibrotic diseases such as interstitial lung disease, myocardial fibrosis, glomerulopathies, aberrant skin scarring, chronic liver disease, and other fibrotic disorders.Conclusion: Given the increasing incidence of chronic fibrotic conditions, pirfenidone emerges as a potential therapeutic option for these patients. However, further clinical trials are necessary to confirm its therapeutic efficacy in various fibrotic diseases. This review aims to highlight the current evidence of pirfenidone's effects in multiple fibrotic conditions.
- 5 July 2024
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 12 (7) , e1335
Top Cited PapersOpen AccessPirfenidone use in fibrotic diseases: What do we know so far?
Background: Pirfenidone has demonstrated significant anti‐inflammatory and antifibrotic effects in both animal models and some clinical trials. Its potential for antifibrotic activity positions it as a promising candidate for the treatment of various fibrotic diseases. Pirfenidone exerts several pleiotropic and anti‐inflammatory effects through different molecular pathways, attenuating multiple inflammatory processes, including the secretion of pro‐inflammatory cytokines, apoptosis, and fibroblast activation.Objective: To present the current evidence of pirfenidone's effects on several fibrotic diseases, with a focus on its potential as a therapeutic option for managing chronic fibrotic conditions.Findings: Pirfenidone has been extensively studied for idiopathic pulmonary fibrosis, showing a favorable impact and forming part of the current treatment regimen for this disease. Additionally, pirfenidone appears to have beneficial effects on similar fibrotic diseases such as interstitial lung disease, myocardial fibrosis, glomerulopathies, aberrant skin scarring, chronic liver disease, and other fibrotic disorders.Conclusion: Given the increasing incidence of chronic fibrotic conditions, pirfenidone emerges as a potential therapeutic option for these patients. However, further clinical trials are necessary to confirm its therapeutic efficacy in various fibrotic diseases. This review aims to highlight the current evidence of pirfenidone's effects in multiple fibrotic conditions.